Upload
harilal-nambiar
View
258
Download
5
Embed Size (px)
Citation preview
SURGERY FOR FAILING SURGERY FOR FAILING HEARTHEART
Dr.Harilal.V.Nambiar MS, MCh(CTVS), FIACS
Sr. Consultant CT Surgeon
Baby Memorial Hospital
Calicut
Introduction
Heart failure is a global term for the physiological state in which cardiac output is insufficient for the body's needs.
It is a condition in which there is problem with the structure or function of the heart and it impairs the ability to supply sufficient blood flow to meet the body's needs.
IncidenceHeart failure affects nearly 5.7 million people
Roughly 670,000 people are diagnosed with heart failure each year.
It is the leading cause of hospitalization in people older than 65.
1 in every 5 people will develop heart failure .
Incidence (per year)
Prevalence Hospitalization
Cost
• 550,000 new diagnoses
• 300,000 deaths
• 1-2% of population (5 million )
•6 days (average)
50% re -hospitalized within 6 months
•1-2% total health care
spending$ 35 billion
Mortality
80% of men and 70% of women with less than 65 years of age and HF will die within 8 years
Up to 42% of patients die of HF within 5 years of hospitalization of HF.
Sudden cardiac death is 6 to 9 times more likely in a HF patient as compared to the general population.
Acute heart failure:
A sudden change in heart function
related to some new event that has caused
damage to the heart.
Chronic heart failure:
A gradual decline of heart function over a period of
time. Often the body compensates slowly for the
loss of heart function.
Causes Acute Heart
FailureMyocardial InfarctionPulmonary EmbolismMyocarditis Post-partum
Cardiomyopathy Acute worsening of CHFAcute HTx RejectionTrauma
Chronic Heart Failure
Coronary artery disease Idiopathic cardiomyopathy Peripartum
cardiomyopathyDilated cardiomyopathyIschemic cardiomyopathyValvular diseaseCongenital heart disease
NYHA Functional Classification
Class Description
I No limitation of physical activity - ordinary physical activity doesn't cause tiredness, heart palpitations, or shortness of breath
II (Mild) Slight limitation of physical activity, comfortable at rest, but ordinary physical activity results in tiredness, heart palpitations, or shortness of breath
III (Moderate
)
Marked or noticeable limitations of physical activity, comfortable at rest, but less than ordinary physical activity causes tiredness, heart palpitations, or shortness of breath
IV (Severe)
Severe limitation of physical activity, unable to carry out any physical activity without discomfort. Symptoms also present at rest. If any physical activity is undertaken, discomfort increases.
AHA/ACC 2009 - Staging System of Heart
Stage Description Examples
A People at high risk for developing heart failure but without structural heart disease or symptoms of heart failure. Encompasses “pre heart failure” where intervention with management can overt Progression to symptoms
CAD (coronary artery disease), diabetes, hypertension, metabolic syndrome, obesity, using cardiotoxins or alcohol, family history of cardiomyopathy, cerebrovascular accident (CVA), personal history of rheumatic fever
B People with structural heart disease but without signs and symptoms of heart failureNYHA Class I
Left ventricular hypertrophy (LVH) or reduced left ventricular ejection fraction (LVEF), asymptomatic valvular heart disease, previous MI
C People with structural heart disease with prior or current symptoms of heart failureNYHA Class II and III
Known structural heart disease with dyspnea, fatigue, inability to exercise
D People who have advanced heart failure and severe symptoms difficult to manage with standard treatmentNYHA Class IV
Marked symptoms at rest despite maximal medical therapy, with recurrent hospitalizations
Acute Heart Failure – Rx Options
IABP
ECMO
TANDEM HEART
IMPELLA
IABP• Device placed via the femoral artery
(in the leg) to increase heart blood flow.
• Pros: – Can be placed and removed by a
catheter.– Will allow increased heart and brain blood
flow– Reduce the after load– Reduce myocardial O2 demand
• Cons: – Lack of active cardiac support– Need some residual LV function– Less effective in arrhythmias
ECMO• Blood is removed from the
venous system either peripherally via cannulation of a femoral vein or centrally via cannulation of the right atrium, – Oxygenate– Extract carbon dioxide
• Blood is then returned back to the body either peripherally via a femoral artery or centrally via the ascending aorta.
• Full cardiopulmonary bypass
• Provides body with oxygenated blood
• Provides body with full cardiac output
• Allows heart and lungs to rest as body recovers from injury and insult
Pros: Can be placed percutaneously anywhere
Provides full heart and lung support
Cons: Must be removed surgically
Need trained staff to monitor and adjust 24 hrs/day while on support Have increased bleeding and vascular complications
Centrifugal flow pump placed percutaneously
Designed to augment left ventricular output and rest left ventricle
Can augment cardiac output up to 5
LPM
Tandem Heart
• Newer generation
magnetic levitation
Centifugal pump rotates in
contact-free manner.
• Increased durability.
• Minimal thrombus and
hemolysis
No evidence to show superiority to conventional therapy.
•Theoretical advantage to allowing the left ventricle to rest and provide the body with support.
•No mechanism to deal with right ventricular failure.
•Trial starting now to determine efficacy versus other devices
Pros: - Can fully augment LV output.
- Placed & removed percutaneously
Cons: - Must have skilled person to place the cannula trans- septaly. - Cannula position is difficult to
control and can migrate
ImpellaAxial flow pumpMiniaturized impellar pump
in catheterHelical catheter tip placed
across aortic valve and left ventricle
Percutaneous or direct placement
Flow 4.5L/minBridge to recovery
Impella RP• Catheter-based
percutaneous VAD (22 Fr pump mounted on a 11 Fr catheter)
• Treatment: Right ventricular dysfunction
• Flow: > 4 L/min• Duration of support: up to
14 days• Pump Inflow: Inferior Vena
Cava (IVC) Pump Outflow: Pulmonary Artery (PA)
AdvantagesSmall pumpPercutaneously placedEasy removalNo need for trans septal punctureDisadvantages
Hemolysis Difficulty of placement in PVD
CHF – Rx OptionsCABGVALVE SURGERYSURGICAL VENTRICULAR RESTORATIONRESTRAINT DEVICESVENTRICULAR ASSIST DEVICESTOTAL ARTIFICIAL HEARTHEART TRANSPLANT
CABGLVEF ≤ 0.35
CAD suitable for CABG
anatomically.
Left main CAD ≥ 50% stenosis
Class III angina or greater
Viable(Hibernating)
myocardium(5/12 segments) –
Cardiac MRI/Dobutamine stress
echo
In patients with HF, LVD and CAD amenable
to surgical revascularization, CABG added to
intensive medical therapy (MED) will decrease
all-cause mortality compared to MED alone.
3% (CABG+Med) Vs 31%(Med alone)
Benefits
Reduced mortality rates
Improved NYHA classification
Favorable alteration of LV geometry
Increased LVEFs
Valve SurgeryAVR indicated in
Symptomatic HF in sev AS/AR
Asymptomatic patients with sev AS/AR & EF <50%
LV contractile reserve assessed by Dobutamine
stress echo.
Distinguish heart failure due to valvar disease or
cardiomyopathy – Ischemic / restrictive.
If contractile reserve present and a valvar
problem will benefit from Sx.
No contractile reserve / Cardiomyopathy treated
with
Aorto apical conduit/LVAD/Percutaneous valve/HTx
Mitral Valve Ischemic MR•Ischemic MR is a ventricular problem.•Papillary muscle rupture.•Stretching/tenting of mitral leaflet•Alteration in LV geometry, annular dilatation contributes to volume overload, ↑ wall tension, exacerbate failure
Ischemic MR• Sx will reverse the cycle of excess ventricular volume,
ventricular unloading and promoting myocardial remodeling.
Annuloplasty + CABG with chordal shortening/re location
Mitral valve replacement with chordal preservation. Isolated MVR not recommended.
Organic MR
Early Sx before LV dysfunction sets in(EF>50%)
Outcomes are poor with EF<30%
SURGICAL VENTRICULAR RESTORATION
History of procedures Ischemic- Batista- Left ventricular aneurysmectomy
Non ischemic - Cardiomyoplasty
Current LV Reconstructive procedures Ischemic
- Dor procedure Non-ischemic
- Acorn Mesh- Myosplint
SVR for Ischemic Cardiomyopathy
Systolic HF leads to an enlarged LV volume to maintain stroke volume
This leads to increase in wall stress due to Laplace's law stress = pressure x radius ÷ 2 x wall thickness
The ventricular geometry becomes less ellipsoid and more spherical leading to progression of left ventricular dysfunction and worsening heart failure.
LV size was a predictor of sudden cardiac death
In the 1990’s studies showed a relationship between LV size and Mortality
LV’s > 4 cm/m2 had a 2 year survival of 49% compared to 75% if < 4 cm/m2
Removing or excluding portions of the dysfunctional
myocardium returns the left ventricular cavity to a
smaller chamber with more normal geometry
This should improve cardiac work efficiency and
theoretically should improve heart failure
symptoms.
Ideally it would also translate into prolonged
survival
• Removal of a section of the left ventricular free wall, between both papillary muscles and extending from the apex to the mitral annulus
• Remaining free edges were re- -approximated and stitched together
• Mitral valve and subvalvular apparatus were either preserved, repaired, or replaced
Partial Left Ventriculectomy(Batista Operation)
Initial experience with the Batista procedure demonstrated an initial increase in LVEF, reduction in heart size, and improvement in clinical functional status
However, of 120 patients Batista reported a 22% operative mortality and 2 year survival of 55%.
Late fatal arrhythmias plagued this
procedure, forcing the use of
concomitant implantable defibrillators
Therefore the Batista procedure has
fallen out of favor and is no longer
considered to be an appropriate option
Left ventricular aneurysmectomy
The first successful surgical correction of an LV
aneurysm occurred in 1957 by Dr. Bailey
Done without off cardiac bypass by placing a
clamp on the base of an aneurysm and passing
suture beneath allowing excision of the
aneurysm.
Dr. Denton Cooley performed a resection of an LV aneurysm one year later on bypass which remained the standard for nearly 30 years
Left ventricular aneurysmectomy
A 2004 ACC/AHA task force concluded that it is
reasonable (class IIa recommendation) to
consider Aneurysmectomy +CABG, in patients
with a left ventricular aneurysm in the setting
of an acute MI who have intractable ventricular
arrhythmias and/or heart failure unresponsive
to medical and catheter-based therapy
LV Reconstruction for Ischemic Cardiomyopathy
Dor procedure also called endo ventricular
circular patch plasty (EVCPP), is an approach to
surgical reconstruction in the setting of post
infarction aneurysm formation first reported in
1985
Advantage to aneurysmectomy is in an attempt
to restore left ventricular geometry
Indications
Anteroseptal MI, with dilated left ventricle (end-
diastolic volume index >100 mL/m2)
Depressed LVEF (20%)
Left ventricular regional dyskinesis or akinesis
>30 % of the ventricular perimeter
Either symptoms of angina, heart failure, or
arrhythmias or inducible ischemia.
Relative contraindications
Systolic pulmonary artery pressure >60
mmHg
Severe right ventricular dysfunction
Regional dyskinesis or akinesis without
dilation of the ventricle
Dor procedure for Ischemic Cardiomyopathy
The operation shortens the long axis, but leaves the short axis length unchanged, producing an increase in ventricular diastolic sphericity while the systolic shape becomes more elliptical
SVR - Dor Procedure
SVR for non ischemic Cardiomyopathy
Cardiomyoplasty, also referred to as “Dynamic
cardiomyoplasty"
Surgical therapy for dilated cardiomyopathy in
which the latissimus dorsi muscle is wrapped
around the heart and paced during ventricular
systole.
Principle is based on the fact that skeletal muscle
can be trained to be fatigue resistant.
Carpentier and Chachques peformed the first successful surgery on a human in 1985
Symptomatic improvement occurred after
cardiomyoplasty
Mechanism for improvement is unclear
Pacemaker synchronization was critical for
obtaining optimal improvement.
Cardiomyoplasty experience has led to other novel approaches to heart failure.
Observations suggested that some patients benefited from the diastolic "girdling" effect of the muscle wrap
This observation led to the development of the Acorn device and Myosplint
SVR for Non-Ischemic Cardiomyopathy(new options)
Acorn device knitted polyester sock
that is drawn up and anchored over the ventricles in order to limit left ventricular dilation
Preliminary data suggest that the device produces an improvement in heart failure symptoms, LVEF, left ventricular end-diastolic dimension, and quality of life
CorCap Cardiac Support Device
The CorCap is designed to:
Provide end-diastolic ventricular support to reduce wall stress and myocardial stretch
Negate the stimuli for ventricular remodeling and promote myocardial reverse remodeling
Reverse progressive dilation and improve cardiac function and patient functional status
Study of 27 pt NYHA class went from mean
2.5 to 1.7
After one year, there is no evidence of
constriction and coronary blood flow reserve
remained normal
MyosplintTwo epicardial pads and a tension wireTwo pads on the surface of the heartWire passes through
the ventriclePlaced under tension to
to create a bi-lobularshape
NYHA functional class went from 3.0 +/- 0.3 at
baseline to 2.1 +/- 0.7 at 6 months (p = 0.001).
The LV ejection fraction significantly increased in
the Myosplint alone group (from 17.1 +/- 4.0% at
baseline to 23.1 +/- 7.2% at 6 months
No serious device-related adverse events or
device failures were observed
Ventricular assist devices
Pulsatile
Heart mate XVE
Abiomed 5000
Thoratec VAD
Non pulsatile
Jarvik 2000
Heart mate II
Heart ware
Heart mate XVE
Pneumatic or vented electric plates
Textured internal surfaces
Only left-sided supportFlows 10L/minBridge to transplantFirst device to be
approved for destination therapy
Need BSA>1.5Limited durability: half
life 18 monthsInfection risk with
percutaneous drive line
Abiomed 5000
ExtracorporealPneumatic pulsatile pumpsUni- or biventricular supportBridge to transplantEasy to insert and operate so used in community hospitalsFlows 6L/min
Thoratec VAD (pVAD/iVAD) Pneumatic, external(pVAD) or internal (iVAD), pulsatile
pump(s)
right-, left-, or bi-ventricular support (RVAD/LVAD/BiVAD)
up to ~7.2 lpm flow
Short- to medium-term use (up to ~1-2 years)
bridge to recovery
bridge to transplant
hospital discharge possible
iVAD pVAD
Jarvik 2000 LVAD Axial-flow (non-pulsatile)
pump
electric, intra-
ventricular
left heart support only
Speed: 8000-12000 rpm
flow: ~3-5 lpm Medium- to long-term therapy
(months to years)
bridge to transplant
(investigational)
Jarvik 2000 LVAD
Heart Mate II• Continuous axial flow pump• Connects LV apex to Aorta• Bypasses blood flow from the left
ventricle• Only has exteriorized driveline
connected to external monitor and power source
• Must be placed surgically• Can be used as bridge to transplant
or as destination therapy
Heart Mate II…Pros:
Excellent flow deviceVery durableEasily implantable Has excellent long term efficacy &
data
Cons:Difficult to explant Need chronic anticoagulation Device does have defined lifespan Patient must be of a certain size to
accommodate device
Heart ware• Continuous axial flow pump• Connects LV apex to Aorta• Bypasses blood flow from the left
ventricle• Only has exteriorized driveline
connected to external monitor and power source
• Must be placed surgically• Can be used as bridge to transplant
or as destination therapy• Small device can be placed in any
body habitus• Can be used for biventricular long-
term support• Currently on trial
Device complicationsEarly
BleedingRight sided heart failureProgressive multi organ system failureArrhythmias
LateInfectionThrombo embolismFailure of device
Total Artificial Heart
An artificial heart is a mechanical device
that replaces the heart. Artificial hearts are
typically used in order to bridge the time to
heart transplant, or to permanently replace
the heart in case transplantation is
impossible.
IndicationsBridge to TxPatient at risk of imminent death from non
reversible bi-ventricular failurePost MI-VSRIntractable arrhythmias/ RV failureDestination RxPatients unfit for Tx-Malignancy, Systemic
disease(amylodosis)
Types of Artificial Heart
Jarvik 7Robert Jarvik, MD is widely
known as the inventor of the first successful permanent artificial heart, the Jarvik 7.
In 1982, the first implantation of the Jarvik 7 in patient Barney Clark caught the attention of media around the world.
Syncardia - Cradiowest TAH
Types of Artificial Heart AbioCorThe AbioCor is the artificial heart is
developed by Abiomed .The AbioCor heart, which is composed of titanium and plastic, connects to four locations:
Right atrium Left atrium Aorta Pulmonary artery
Types of Artificial Heart
Advantage No External drive linesTrans cutaneous transmission of energyReduced chance of infectionDisadvantageLarge sizeImplantable only in 50% men and 20%
women
Carmat Bioprosthetic TAH – Carpentier, France 2013Made of biologic & Synthetic polymers.It has the shape & Volume of normal
heart.Weight - 900gms(3x of normal heart).Provided with multiple sensors for
optimizing CO in response to various demands.
Powered by lithium battery.Fits into 75% men & 25% women.Cost - $200,000(₹ 1,20,00000).
HEART TRANSPLANTReplacement of the
failing heart with a heart from a suitable donor.
Cardiac transplantation is currently the only established surgical approach (excluding AVR and CABG) for the treatment of refractory HF as listed in the 2005 ACC/AHA heart failure guidelinesSmall number of available donor heartsInapplicable in older pts or those with
comorbid conditions
Class I Indications for Cardiac Transplantation
Cardiogenic shock requiring mechanical assistance.Refractory heart failure with continuous inotropic infusion.NYHA functional class 3 and 4 with a poor 12 month
prognosis.Progressive symptoms with maximal therapy.Severe symptomatic hypertrophic or restrictive
cardiomyopathy.Medically refractory angina with unsuitable anatomy for
revascularization.Life-threatening ventricular arrhythmias despite aggressive
medical and device interventions.Cardiac tumors with low likelihood of metastasis.Hypoplastic left heart and complex congenital heart
disease.
• Patients should receive maximal medical therapy
before being considered for transplantation. They
should also be considered for alternative surgical
therapies including CABG, valve repair / replacement,
cardiac septalplasty, etc.
• VO2 has been used as a reproducible way to
evaluate potential transplant candidates and their long
term risk. peak VO2 <10 had the greatest survival
benefit.
Contra IndicationActive infectionActive malignancyActive systemic diseasePVR > 4Wood unitsOn going drug abuseMental instabilityLack of complianceAge > 65 Years
Procedures Orthotopic Tx
Bi Atrial technique(Shum way)
Bi caval Technique
Hetrotopic Tx
Donor Heart Procurement
Median sternotomy. Cold cardioplegia given one litre. Heart removed Kept in Cold University of Wiscosin solution. Cardiac ischemia time 180 min
Donor allograft preparation for orthotopic heart transplantation. Pulmonary vein orifices joined to form left atrial cuff.
First suture is placed at the level of the left superior pulmonary vein.
Implantation of
allograft (continued).
Left atrial anastomosis.
Right atrial anastomosis.
•Aortic anastomosis.
• Completed transplant• Pacing wires on donor portion of right atrium and ventricle• Pericardium left open
*
Orthotopic HTx
• Left atrial anastomosis performed• Separate inferior and superior vena caval anastomosis
*
•Bicaval is preferred one today.• described by Lower and colleagues.•Achieves more anatomic position, •Neutralizes potential for atrial enlargement•Less tricuspid regurge•Better hemodynamic performance.
• Heterotopic heart transplants are indicated in patients with - irreversible pulmonary hypertension or - significant donor-recipient size mismatch.
• Donor allograft preparation for heterotopic heart transplantation.
•Completed Hetrotopic Tx.
Immuno suppression CyclosporinCorticosteroidsMycophenolate mofetilFK-506 (tacrolimus):Antilymphocyte globulin
Muromonab-CD3 (OKT3Rapamycin
Complications:Hyperacute RejectionAcute Cellular RejectionVascular (humoral) RejectionInfection – CMVToxoplasma gondiiPneumocystis cariniiAspergillus organismsMalignancyHypertensionDyslipidemiaTricuspid Regurgitation
Outcome1 year survival rate 81.8%
5 year survival rate 69.8%
10 year survival rate 50%Functional status of the patient is excellent